Action 4151 KYOWA KIRIN CO. LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Kyowa Kirin Co. Ltd.

Actions

4151

JP3256000005

Marché Fermé - Japan Exchange
Autres places de cotation
 08:00:00 16/07/2024 		Varia. 5j. Varia. 1 janv.
3 100 JPY -0,23 % Graphique intraday de Kyowa Kirin Co. Ltd. +5,86 % +30,80 %
03/07 Kyowa Kirin rachète des actions MT
07/05 Le bénéfice de Kyowa Kirin en hausse de 15 % au premier trimestre MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Kyowa Kirin : Announces Application for Additional Formulation of “LUMICEF® Subcutaneous Injection 210 mg Pen” in Japan
PU
Kyowa Kirin : Announces Approval for Partial Change of Approved Indication of G-Lasta® for the Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Blood Stem Cell Transplantation in Japan (243KB)
PU
Kyowa Kirin : Transcript of Results Briefing Fiscal 2024 First Quarter (0B)
PU
Kyowa Kirin : Results Presentation Fiscal 2024 First Quarter (0B)
PU
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
AQ
Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ (istradefylline) and Other Parkinson's Disease Add-On Therapies
AQ
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of Mycosis Fungoides and Sézary Syndrome
BU
Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024
AQ
Kyowa Kirin : Partial Corrections to “Notice of Convocation of the 101st Ordinary General Meeting of Shareholders” (0B)
PU
Kyowa Kirin Co., Ltd - Notice regarding Completion of Share Acquisition of Orchard Therapeutics plc
AQ
Kyowa Kirin Successfully Completes Acquisition of Orchard Therapeutics, a Global Gene Therapy Leader for Rare Diseases
BU
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
AQ
Eczema Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, AstraZeneca, Kyowa Kirin, and Others
AQ
Kyowa Kirin : Transcript of Results Presentation Fiscal 2023 Third Quarter (text) (0B)
PU
Kyowa Kirin : Consolidated Financial Summary (IFRS) Fiscal 2023 Third Quarter (0B)
PU
Kyowa Kirin : Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2023 Third Quarter (0B)
PU
Kyowa Kirin : Results Presentation Fiscal 2023 Third Quarter (0B)
PU
Kyowa Kirin : Announces Presentations of the Results of Phase 3 Studies of PHOZEVEL® for Patients with Hyperphosphatemia Undergoing Dialysis in Japan at the American Society of Nephrology Meeting (291KB)
PU
Kyowa Kirin Announces Three Abstracts and A Symposium at the European Academy of Dermatology and Venereology Congress 2023
AQ
Kyowa Kirin to Acquire Orchard Therapeutics
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 4151
  4. Actualités Kyowa Kirin Co. Ltd.
  5. Communiqués